Eplerenone

Generic Name
Eplerenone
Brand Names
Inspra
Drug Type
Small Molecule
Chemical Formula
C24H30O6
CAS Number
107724-20-9
Unique Ingredient Identifier
6995V82D0B
Background

Eplerenone, an aldosterone receptor antagonist similar to spironolactone, has been shown to produce sustained increases in plasma renin and serum aldosterone, consistent with inhibition of the negative regulatory feedback of aldosterone on renin secretion. The resulting increased plasma renin activity and aldosterone circulating levels do not overcome the ef...

Indication

For improvement of survival of stable patients with left ventricular systolic dysfunction (ejection fraction <40%) and clinical evidence of congestive heart failure after an acute myocardial infarction.

Associated Conditions
Hypertension, LVEF <40% Congestive heart failure, Chronic heart failure with reduced ejection fraction (NYHA Class II)
Associated Therapies
-
Clinical Trials
Related News

Treatment of Supine Hypertension in Autonomic Failure

First Posted Date
2005-09-22
Last Posted Date
2017-10-13
Lead Sponsor
Vanderbilt University
Target Recruit Count
152
Registration Number
NCT00223717
Locations
🇺🇸

Vanderbilt University, Nashville, Tennessee, United States

Aldosterone and Vascular Disease in Diabetes Mellitus

First Posted Date
2005-09-22
Last Posted Date
2008-01-03
Lead Sponsor
Brigham and Women's Hospital
Target Recruit Count
46
Registration Number
NCT00214825
Locations
🇺🇸

Brigham and Women's Hospital, Boston, Massachusetts, United States

EWISE: Study of Eplerenone in Women With Chest Pain, Coronary Vascular Dysfunction and Evidence of Myocardial Ischemia

First Posted Date
2005-09-16
Last Posted Date
2013-10-14
Lead Sponsor
University of Florida
Target Recruit Count
70
Registration Number
NCT00187889
Locations
🇺🇸

University of Florida, Gainesville, Florida, United States

A Study to Evaluate the Efficacy and Safety of Eplerenone in the Treatment of Hypertension in Children.

Phase 3
Completed
Conditions
Hypertension
First Posted Date
2005-09-07
Last Posted Date
2020-12-22
Lead Sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Target Recruit Count
320
Registration Number
NCT00147589
Locations
🇿🇦

Pfizer Investigational Site, Cape Town, South Africa

Compare Effectiveness of Eplerenone vs Atenolol in Reversing the Remodelling Resistance Arteries in Subjects With HT

Phase 4
Completed
Conditions
Hypertension
First Posted Date
2005-09-07
Last Posted Date
2008-04-15
Lead Sponsor
Pfizer
Target Recruit Count
34
Registration Number
NCT00147563
Locations
🇨🇦

Pfizer Investigational Site, Montreal, Quebec, Canada

The Long-term Study to Evaluate the Safety of Eplerenone in the Treatment of Hypertension in Children Aged 6 to 16 Years

Phase 3
Completed
Conditions
Hypertension
First Posted Date
2005-09-07
Last Posted Date
2020-12-22
Lead Sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Target Recruit Count
140
Registration Number
NCT00147615
Locations
🇷🇺

Pfizer Investigational Site, St. Petersburg, Russian Federation

Effectiveness of Eplerenone to Improve Target Organ Damage in Patients With Resistant Arterial Hypertension

Phase 3
Completed
Conditions
Essential Hypertension
Interventions
Drug: placebo
Drug: eplerenone
First Posted Date
2005-08-30
Last Posted Date
2013-04-17
Lead Sponsor
University of Erlangen-Nürnberg Medical School
Target Recruit Count
85
Registration Number
NCT00138944
Locations
🇩🇪

CRC Medical Department IV, Erlangen, Germany

Effects of Eplerenone on Left Ventricular Remodelling Following Heart Attack

Phase 4
Completed
Conditions
Myocardial Infarction
First Posted Date
2005-08-19
Last Posted Date
2006-04-10
Lead Sponsor
NHS Greater Glasgow and Clyde
Target Recruit Count
100
Registration Number
NCT00132093
Locations
🇬🇧

Western Infirmary, Glasgow, Scotland, United Kingdom

Aldosterone Antagonism in Diastolic Heart Failure

First Posted Date
2005-04-15
Last Posted Date
2011-09-08
Lead Sponsor
US Department of Veterans Affairs
Target Recruit Count
48
Registration Number
NCT00108251
Locations
🇺🇸

Michael E DeBakey VA Medical Center, Houston, Texas, United States

The Purpose of This Study is to Determine if Eplerenone is Effective in Treatment of Mild to Moderate Heart Failure

Phase 4
Completed
Conditions
Heart Failure, Congestive
First Posted Date
2004-05-14
Last Posted Date
2020-12-22
Lead Sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Target Recruit Count
250
Registration Number
NCT00082589
Locations
🇺🇸

Pfizer Investigational Site, Madison, Wisconsin, United States

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy